SavedAdd your journal

Journals / Viral Hepatitis Journal / 2014 / Cilt: 20 - Sayı: 3

Talasemi Majörlü Hastada Kronik Hepatit C Tedavisi: Olgu Sunumu

Chronic Hepatitis C Treatment in a Thalassemia Maj or Patient: A Case Report

Kaya Hüseyin SÜER
Dilara İNAN
Pages
134–137
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This paper presents the outcomes and side effects of treatment given to thalassemia major patients with chronic hepatitis C.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thalassemia major patients with chronic hepatitis C have increased risk for developing fibrosis and hepatocellular carcinoma due to liver damage caused by these two diseases.
📊
Key Findings & Data:Although the current treatment of chronic hepatitis is based on binary combinations, the use of ribavirin in combination with peginterferon alfa- 2a or b in patients with hemoglobinopathies is not recommended by the treatment guidelines.
💡
Conclusion & Impact:This paper presents the outcomes and side effects of treatment given to thalassemia major patients with chronic hepatitis C.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Thalassemia major patients with chronic hepatitis C have increased risk for developing fibrosis and hepatocellular carcinoma due to liver damage caused by these two diseases. Although the current treatment of chronic hepatitis is based on binary combinations, the use of ribavirin in combination with peginterferon alfa- 2a or b in patients with hemoglobinopathies is not recommended by the treatment guidelines. However, it is observed that there have been changes in the applications presented in the guidelines over the years. This paper presents the outcomes and side effects of treatment given to thalassemia major patients with chronic hepatitis C.

Özet

Talasemi majör hastalarında saptanan kronik hepatit C olgularında karaciğer üzerinde iki hastalığın oluşturduğu hasar ile fibrozis ve hepatoselüler karsinom gelişme riski artmaktadır. Sadece kronik hepatit C tedavisinde kullanılan rehberlerin önerilerinde tedavi ikili kombinasyonlar ile başlamakla beraber hemoglobinopatisi olanlarda ribavirin kullanımı önerilmemektedir. Ancak yıllar içinde rehberlerdeki uygulamalarda değişikliler olduğu görülmektedir. Bu yazıda talasemi majör hastasında saptanan kronik hepatit C nedeniyle verilen tedavi, gelişen yan etkiler ve tedavi sonucu sunulmuştur.

🔖

Cite This Article

SÜER, K. H., İNAN, D. (2014). Talasemi Majörlü Hastada Kronik Hepatit C Tedavisi: Olgu Sunumu. Viral Hepatitis Journal, Cilt: 20 - Sayı: 3, 134–137. https://ajindex.com/articles/332836

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. McCaughan GW, omata M, amarapurkar D, Bowden S, Chow WC, Chutaputti a, Dore G, Gane e, Guan R, hamid SS, hardikar W, hui Ck, Jafri W, Jia JD, lai MY, Wei l, leung n, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Special report asian Pacific association for the Study of the liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol and hepatol. 2007; 22:615-633
  2. Strader DB, Wright T, Thomas Dl, Seeff lB. aaSlD PRaCTICe GuIDelIne Diagnosis, Management and Treatment of hepatitis C. hepatology. 2004; 39(4):1147-1171
  3. Bircan İ, Şişli S, Güven a, Çalı Ş, Yeğin o, ertuğ h, Güven aG, akar n. hemoglobinopathies in the district of antalya,Turkey. Pediatr hematol oncol. 1993; 10(3): 289-293. 4. angelucci e, Pilo F. Treatment of hepatitis C in patients with thalassemia. haemotologica. 2008; 93(8): 1121-1123. 5. angelucci e, Muretto P, nicolucci a, Baronciani D, erer B, Gaziev J, Ripalti M, Sodani P, Tomassoni S, visani G, lucarelli G. effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002; 100(1): 17-21. 6. ardalan Fa, osquei MR, Toosi Mn, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrozis: a retrospective cross-sectional study. BMC Gastroenterol. 2004; 4:17. 7. hamidah a, Thambidorai CR, Jamal R. Peginterferon alfa-2b and Ribavirin in Thalasameia/Chronic hepatitis C virus-CoInfected non-Responder to Standard Interferon –Based Therapy. Med J Malaysia 2005; 60(4): 517-519
  4. Carithers Rl, emerson SS. Therapy of hepatitis C: metanalysis of interferon alpha-2b trials. hepatology 1997; 26: 83-88
  5. Booth JCl, o’Grady J, neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001; 49:1-21
  6. Di Marco v, Capra M, angelucci e, Borgna-Pignatti C, Telfer P, harmatz P, kattamis a, Prossamariti l, Filosa a, Rund D, Gamberini MR, Cianciulli P, De Montalembert M, Gagliardotto F, Foster G, Grangè JD, Cassarà F, Iacono a, Cappellini MD, Brittenham GM, Prati D, Pietrangelo a, Craxì a, Maggio a; Italian Society for the Study of Thalassemia and haemoglobinopathies; Italian association for the Study of the liver. Management of chronic viral hepatitis in patient with Thalassemia: reccomendatios from an international panel. Blood. 2010; 116(16): 2875-2883
  7. Tine F, Magrin S, Craxı aD, Pagliaro l. In